We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
ZeptoMetrix an Antylia scientific company

Download Mobile App




Post-Infection Zika Virus Shed in Saliva and Semen

By LabMedica International staff writers
Posted on 19 Oct 2016
Results of a study of the mechanism of Zika virus infection in two primate models demonstrated that the virus spread rapidly into the nervous system of healthy animals and that shedding of the virus in saliva and semen underscored possible concern for additional neurological complications and non-mosquito-mediated transmission in humans.

Infection with Zika virus has been associated with serious neurological complications and fetal abnormalities. More...
However, the dynamics of viral infection, replication and shedding are poorly understood.

To obtain a better understanding of the mechanism that underlies Zika virus infection, investigators at Beth Israel Deaconess Medical Center (Boston, MA, USA) colleagues infected 36 rhesus and cynomolgus macaques with subcutaneous injections of strains of the Zika virus from Puerto Rico and Thailand. Over the next four weeks, the investigators analyzed blood, tissues, cerebrospinal fluid (CSF), and mucosal secretions for the presence of Zika virus RNA and monitored the animals' immune response during early infection.

They reported in the October 3, 2016, online edition of the journal Nature Medicine that viral RNA could be detected in blood plasma as early as one day after infection. Viral RNA was also detected in saliva, urine, CSF, and semen, but only transiently in vaginal secretions. Although viral RNA during primary infection was cleared from blood plasma and urine within 10 days, viral RNA was detectable in saliva and seminal fluids until the end of the study, three weeks after the disappearance of viral RNA from the blood. Zika RNA was also identified in tissues, including the brain and male and female reproductive tissues, during early and late stages of infection.

The control of primary Zika virus infection in the blood was correlated with rapid innate and adaptive immune responses. Re-infection of six animals 45 days after primary infection with a heterologous strain of the virus resulted in complete protection, which suggested that primary Zika virus infection elicited protective immunity.

“We found, initially, that the virus replicated very rapidly and was cleared from the blood in most animals within ten days,” said senior author Dr. James B. Whitney, assistant professor of medicine at Beth Israel Deaconess Medical Center. “Nevertheless, we observed viral shedding in other bodily fluids such as spinal fluid, saliva, urine, and semen up to three weeks after the initial infection was already cleared. Of particular concern, we saw extraordinarily high levels of Zika virus in the brain of some of the animals – the cerebellum, specifically – soon after infection. Only one in five adults have noticeable symptoms of infection. However, if our data translate to humans, there may be need for enhanced clinical vigilance for any persons presenting with unusual neurological symptoms, and they should be tested for Zika infection.”

“We found that male-to-female transmission might be easier, while female-to-male may be less likely,” said Dr. Whitney. “Nonetheless, the high levels of Zika we observed in the uterus underscore the danger to a developing fetus.”

Related Links:
Beth Israel Deaconess Medical Center


Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Verification Panels for Assay Development & QC
Seroconversion Panels
POCT Fluorescent Immunoassay Analyzer
FIA Go
Gold Member
ESR Analyzer
miniiSED™
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.